Disclaimer : This medical information is intended only for healthcare professionals in India. The products discussed herein may have different product labeling in other countries. The information within this site is intended to provide balanced, scientific, and evidence based answers to unsolicited medical questions. For full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events, please submit a medical information request. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. The website does not sell/ purchase any medicine.
Description
Description
COMPOSITION: Each tablet contains Pazonpanib 400 mg
INDICATION: Pazopanib 400 mg is a potent muti-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1 ,-2, and -3, platelet- derived growth factor (PDGFR) -a, and -b, and stem cell factor receptor (c-KIT), with IC 50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
Pazokast is indicated for the treatment of patients with advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy. It is also indicated for the treatment of patients with advanced renel cell carcinoma.
PACKING: 30 Tablets / Bottle
Download Product PDF Attachment